EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA

EntreMed (Nasdaq: ENMD ) announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug Administration (CFDA). The ongoing